KANSAS CITY, Mo.--(BUSINESS WIRE)-- Teva Neuroscience today announced the tenth anniversary of Team COPAXONE® (glatiramer acetate injection), a group of 10 inspirational individuals who have challenged their multiple sclerosis (MS) diagnosis to pursue the active lives they love through a commitment to healthy living. In its 10 years, the Team’s members have ranged from triathlete to snowmobiler, from racecar driver to LPGA caddy, but all have shared a common conviction to live their lives to the fullest despite an MS diagnosis while promoting the benefits of healthy diet, exercise and drug therapy adherence, though individual results may vary.
In celebration of this decade of achievement, Teva Neuroscience is looking for an eleventh extraordinary member to join the Team. To be considered, a person must share the Team’s common goal of refusing to let MS stand in the way of their dreams and be actively engaging in a sport or pursuit they love. Submissions will be screened for eligibility, and top entries will be posted to the Team’s Web site for public voting. The newest member of Team COPAXONE® will be announced in late 2010 and will receive sponsorship support to participate in their chosen activity.
Those wishing to be considered to join Team COPAXONE® should visit www.TeamCopaxone.com by September 1, 2010.
“When I was first diagnosed, I feared losing the ability to ride my horses,” said competitive barrel horse racer Laura Kimball, “but it’s a different fear for everyone who receives this kind of news. Being a part of Team COPAXONE® for nearly two years has given me the opportunity to share with others the success that I’ve found by maintaining a daily commitment to my health. We’re so excited to welcome a new member to our efforts – there are so many people with amazing stories to share.”
Highlights from the Team’s upcoming year include:
MS is a chronic, often disabling disease that attacks the central nervous system. Symptoms may be mild, such as numbness in the limbs, or severe, such as paralysis or loss of vision. The progress, severity, and specific symptoms of MS are unpredictable and vary from one person to another. In the U.S. today, there are approximately 400,000 people with MS — with 200 more people diagnosed every week. Worldwide, MS is thought to affect more than 2.1 million people.
For more information on the members of Team COPAXONE® and the 10 Years & Counting new member quest, please visit http://www.copaxone.com/NewlyDiagnosed/teamCopax.aspx.
COPAXONE® (glatiramer acetate injection) is indicated for the reduction of the frequency of relapses in relapsing-remitting multiple sclerosis, including patients who have experienced a first clinical episode and have MRI features consistent with multiple sclerosis.
Additional Safety Information about COPAXONE®
The most common side effects of COPAXONE® are injection site reactions, such as redness, pain, swelling, itching, or a lump at the site of injection. A permanent indentation under the skin at the injection site may occur, due to a local destruction of fatty tissue. Be sure to follow proper injection technique and inform your doctor of any skin changes. Some people report a short-term reaction right after injecting COPAXONE®. This reaction can involve flushing (feeling of warmth and/or redness), chest tightness or pain with heart palpitations, anxiety and trouble breathing. Keep in mind that these symptoms generally appear within minutes of an injection, last about 15 minutes, and go away by themselves without further problems. If symptoms become severe, call the emergency phone number in your area. Do not give yourself any more injections until your doctor tells you to begin again.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
COPAXONE® (glatiramer acetate injection) is now approved in 51 countries worldwide, including the United States, Canada, Mexico, Australia, Israel, and all European countries. In North America, COPAXONE® is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA). In Europe, COPAXONE® is marketed by Teva Pharmaceutical Industries Ltd. and sanofi-aventis. COPAXONE® is a registered trademark of Teva Pharmaceutical Industries Ltd.
See additional important information at http://www.copaxone.com/pi/index.html or call 1-800-887-8100 for electronic releases. For hardcopy releases, please see enclosed full prescribing information.
About Teva Neuroscience
Teva Neuroscience is dedicated to investigating, developing and marketing ground-breaking products and technologies, with emphasis on cutting-edge treatments for patients who are living with neurological conditions, including multiple sclerosis (MS) and Parkinson’s disease (PD). Therapies marketed by Teva Neuroscience include COPAXONE® (glatiramer acetate injection) for relapsing-remitting multiple sclerosis (RRMS) and AZILECT® (rasagiline tablets) for the treatment of PD.
Teva Neuroscience’s suite of innovative products continues to demonstrate the company’s commitment to fulfilling unmet medical needs and has helped the company evolve into a global leader in RRMS. Teva Neuroscience is a North American division of Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company. Teva Neuroscience is proud of the role it plays in providing effective treatment options to patients worldwide. For more information, please visit www.tevaneuro.com or www.tevaclinicaltrials.com.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management's current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic equivalents, the extent to which we may obtain U.S. market exclusivity for certain of our new generic products and regulatory changes that may prevent us from utilizing exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, including that relating to the generic versions of Neurontin®, Lotrel® and Protonix®, the extent to which any manufacturing or quality control problems damage our reputation for high quality production, the effects of competition on sales of our innovative products, especially Copaxone® (including potential generic and oral competition for Copaxone®), the impact of continuing consolidation of our distributors and customers, our ability to identify, consummate and successfully integrate acquisitions, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, intense competition in our specialty pharmaceutical businesses, any failures to comply with the complex Medicare and Medicaid reporting and payment obligations, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation, adverse effects of political or economical instability, major hostilities or acts of terrorism on our significant worldwide operations, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, dependence on the effectiveness of our patents and other protections for innovative products, our ability to achieve expected results through our innovative R&D efforts, the difficulty of predicting U.S. Food and Drug Administration, European Medicines Agency and other regulatory authority approvals, uncertainties surrounding the legislative and regulatory pathway for the registration and approval of biotechnology-based products, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities resulting from challenges to our intercompany arrangements, our potential exposure to product liability claims to the extent not covered by insurance, the termination or expiration of governmental programs or tax benefits, current economic conditions, any failure to retain key personnel or to attract additional executive and managerial talent, environmental risks and other factors that are discussed in this report and in our other filings with the U.S. Securities and Exchange Commission ("SEC").
Denise Bradley, 215-591-8974
Sr. Director, North America Corporate Communications
KEYWORDS: United States North America Missouri
INDUSTRY KEYWORDS: Health Pharmaceutical Philanthropy Research Other Philanthropy Science